Infectious Diseases Research

Below are current clinical trials.

273 studies in Infectious Diseases Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. A Study to Evaluate the Relationship Between Vaginal and Lower Urinary Tract Microbiomes and Infection After A Hysterectomy

   Rochester, Minn.

   The purpose of this study is to learn more about the microbes (bacteria) that live in the vagina and the bladder. The investigators are doing this research study to understand the relationship between microbes (the microbiome) and the occurrence of urinary tract infection following surgical removal of the uterus and pelvic organ prolapse repair.

2. A Study Comparing Measurements of Response to Antiviral Treatments for Liver Transplant Patients that have Recurrent Hepatitis C

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to measure the rates of continuing viral presence, following anti-viral therapy with combined Peg-Interferon and Ribavirin in patients that have had a liver transplant, are immune suppressed with Neoral or tacrolimus, and have a recurring infection with the Hepatitis C virus.

3. Comparison of Respiratory Pathogen Detection in Upper Versus Lower Respiratory Tract Samples using the Biofire Filmarray Respiratory Panel

   Rochester, Minn.

   The purpose of this study is to compare the performance of the FilmArray Respiratory Panel in nasopharyngeal (NP) swabs and bronchoalveolar lavage (BAL) fluid collected from immunocompromised hosts (ICH).

4. Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

   Rochester, Minn.

   This is the first prospective, multi-center, double-blinded, randomized controlled study of a microbiota suspension derived from intestinal microbes. Patients who have had at least two recurrences of C. difficile infection (CDI) after a primary episode and have completed at least two rounds of standard-of-care oral antibiotic therapy or have had at least two episodes of severe CDI resulting in hospitalization may be eligible for the study. Patients whose CDI returns in less than 8 weeks after the last assigned study treatment may be eligible to receive up to 2 treatments with RBX2660 in the open-label portion of the study.

5. Assessing Patient Outcomes Following Treatment with Ceftolozane/Tazobactam (C/T)

   Rochester, Minn.

   The purpose of this study is to evaluate the real-world utilization of ceftolozane/tazobactam (C/T) and to assess patient outcomes.

6. Immune Cell Activation of Healthy Human Subjects

   Rochester, Minn.

   The purpose of this research study is to establish a pool of healthy donors who will regularly participate in our research studies of human immunity. The studies in our laboratory investigate the role of human blood cells in immunity to fungal disease and lung fibrosis. Most of our studies require blood that is freshly drawn. Thus, we propose to draw blood on an as needed, ongoing basis.

7. Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

   Scottsdale/Phoenix, Ariz.

   This study will evaluate efficacy and safety information about RBX2660 for the treatment of recurrent Clostridium difficile infection (CDI). Enrolled subjects will receive one treatment with RBX2660 (microbiota suspension).

8. A Study of VE303 for Prevention of Recurrent Clostridium Difficile Infection

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the safety and effectiveness of VE303 for participants with primary C. difficile infection (pCDI) at high risk for recurrence or subjects with recurrent C. difficile infections (rCDI).

9. A Study of a Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV) Infection

   Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to determine whether INO-8000 alone or in combination with INO-9012 (IL-12) is safe and induces a Hepatitis C virus-specific immune response.

10. COVID-19 Serological Assay Validation

    Rochester, Minn.

    The purpose of this research is to evaluate multiple new tests for detection of antibodies to SARS-CoV-2, the cause of COVID19, in blood samples.